Thomas Welte - Nanotechnology

Author Information

Thomas Welte is affiliated with the Biomarker Research Program Center at the Houston Methodist Research Institute, located in Houston, TX, USA. His work is primarily focused on the intersection of nanotechnology, immunotherapy, and RNA biology, contributing significantly to these fields through extensive research and publication.

Research Contributions

Thomas Welte has made substantial contributions to the fields of nanotechnology, immunotherapy, and RNA biology. His research encompasses a variety of topics, including SARS-CoV-2 vaccination responses in transplant recipients, the identification of aptamers with binding specificity to tumor-homing cells, and the role of endothelial dysfunction in severe COVID-19 cases. Additionally, Welte has explored the regulation of splicing factors and the development of nanoplatforms for mRNA therapeutics, showcasing his broad expertise and impact on both fundamental and applied biomedical research.

Aliases

T Welte, T. Welte, Thomas Welte

Publication and Citation Metrics

Metric	Value
Citation Count	5006
H-Index	39
Paper Count	110

Publications:

Variances in Humoral Responses to Different Spike Protein Domains After SARS-CoV-2 Vaccination in Lung and Heart Transplant Recipients

DOI: 10.1016/j.healun.2022.01.260

Year: 2022

Identification of an Aptamer With Binding Specificity to Tumor-Homing Myeloid-Derived Suppressor Cells

DOI: 10.3389/fphar.2021.752934

Year: 2021

Endothelial dysfunction determines severe COVID-19 in combination with dysregulated lymphocyte responses and cytokine networks

DOI: 10.1101/2021.07.08.21260169

Year: 2021

A heparan-sulfate-bearing syndecan-1 glycoform is a distinct surface marker for intra-tumoral myeloid-derived suppressor cells

DOI: 10.1016/j.isci.2021.103349

Year: 2021

An autoinhibitory intramolecular interaction proof-reads RNA recognition by the essential splicing factor U2AF2

DOI: 10.1073/pnas.1913483117

Year: 2020

Nanoplatforms for mRNA Therapeutics

DOI: 10.1002/adtp.202000099

Year: 2020

Abstract B23: PMN-MDSCs enhance CTC metastatic properties through reciprocal interactions via ROS/Notch/Nodal Nodal signaling

DOI: 10.1158/1557-3265.liqbiop20-b23

Year: 2020

Specific inhibition of splicing factor activity by decoy RNA oligonucleotides

DOI: 10.1038/s41467-019-09523-0

Year: 2019

The RNA hairpin binder TRIM71 modulates alternative splicing by repressing MBNL1.

DOI: 10.1101/gad.328492.119

Year: 2019

Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms

DOI: 10.1038/s41556-019-0373-7

Year: 2019

What are the Future Trends in Nanotechnology Funding?

How Does Electrical Conductivity Change?

How Do These Techniques Work?

What Soft Skills are Important?

What is the Future of Programmable Logic in Nanotechnology?

What Are the Key Elements of GHS Labels for Nanomaterials?

What are the Limitations of FIB Lithography?

What are the Applications of Nanolithography?

What are the Key Components in Nanoscale Data Transmission?

What is Nanotechnology and How Does it Influence Electronics?

Partnered Content Networks

Relevant Topics